Cargando…

Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk

BACKGROUND: Musclin is an activity‐stimulated and cardioprotective myokine that attenuates pathological cardiac remodeling. Musclin deficiency, in turn, results in reduced physical endurance. The aim of this study was to assess the prognostic value of circulating musclin as a novel, putative biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Kattih, Badder, Carstens, Daniel C., Boeckling, Felicitas, Rasper, Tina, Pergola, Graziella, Dimmeler, Stefanie, Vasa‐Nicotera, Mariuca, Zeiher, Andreas M., Mas‐Peiro, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075297/
https://www.ncbi.nlm.nih.gov/pubmed/35229655
http://dx.doi.org/10.1161/JAHA.121.022792
_version_ 1784701651738689536
author Kattih, Badder
Carstens, Daniel C.
Boeckling, Felicitas
Rasper, Tina
Pergola, Graziella
Dimmeler, Stefanie
Vasa‐Nicotera, Mariuca
Zeiher, Andreas M.
Mas‐Peiro, Silvia
author_facet Kattih, Badder
Carstens, Daniel C.
Boeckling, Felicitas
Rasper, Tina
Pergola, Graziella
Dimmeler, Stefanie
Vasa‐Nicotera, Mariuca
Zeiher, Andreas M.
Mas‐Peiro, Silvia
author_sort Kattih, Badder
collection PubMed
description BACKGROUND: Musclin is an activity‐stimulated and cardioprotective myokine that attenuates pathological cardiac remodeling. Musclin deficiency, in turn, results in reduced physical endurance. The aim of this study was to assess the prognostic value of circulating musclin as a novel, putative biomarker to identify patients undergoing transcatheter aortic valve implantation (TAVI) who are at a higher risk of death. METHODS AND RESULTS: In this study, we measured systemic musclin levels in 368 patients undergoing TAVI who were at low to intermediate clinical risk (median EuroSCORE [European System for Cardiac Operative Risk Evaluation] II: 3.5; quartile 1–quartile, 2.2%–5.3%), whereby 209 (56.8%) patients were at low and 159 (43.2%) were at intermediate risk. Median preprocedural musclin levels were 2.7 ng/mL (quartile 1–quartile 3, 1.5–4.6 ng/mL). Musclin levels were dichotomized in low (<2.862 ng/mL, n=199 [54.1%]) or high (≥ 2.862 ng/mL, n=169 [45.9%]) groups using cutoff values determined by classification and regression tree analysis. The primary end point was 1‐year overall survival. Patients with low circulating musclin levels exhibited a significantly higher prevalence of frailty, low albumin values, hypertension, and history of stroke as well as higher N‐terminal pro‐B‐type natriuretic peptide. Low musclin levels significantly predicted risk of death in univariable (hazard ratio, 1.81; 95% CI, 1.00–3.53 [P=0.049]) and multivariable (adjusted hazard ratio, 2.45; 95% CI, 1.06–5.69 [P=0.037]) Cox regression analyses. Additionally, low musclin levels in combination with conventional EuroSCORE II suggested improved risk stratification in patients undergoing TAVI who were at low to intermediate clinical risk into subgroups with reduced 1‐year survival rates by log‐rank test (P for trend=0.003). CONCLUSIONS: Circulating musclin is an independent predictor of 1‐year overall survival in patients undergoing TAVI. Combined with EuroSCORE II, circulating musclin might help to improve prediction of mortality in patients undergoing TAVI who are at low to intermediate clinical risk.
format Online
Article
Text
id pubmed-9075297
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90752972022-05-10 Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk Kattih, Badder Carstens, Daniel C. Boeckling, Felicitas Rasper, Tina Pergola, Graziella Dimmeler, Stefanie Vasa‐Nicotera, Mariuca Zeiher, Andreas M. Mas‐Peiro, Silvia J Am Heart Assoc Original Research BACKGROUND: Musclin is an activity‐stimulated and cardioprotective myokine that attenuates pathological cardiac remodeling. Musclin deficiency, in turn, results in reduced physical endurance. The aim of this study was to assess the prognostic value of circulating musclin as a novel, putative biomarker to identify patients undergoing transcatheter aortic valve implantation (TAVI) who are at a higher risk of death. METHODS AND RESULTS: In this study, we measured systemic musclin levels in 368 patients undergoing TAVI who were at low to intermediate clinical risk (median EuroSCORE [European System for Cardiac Operative Risk Evaluation] II: 3.5; quartile 1–quartile, 2.2%–5.3%), whereby 209 (56.8%) patients were at low and 159 (43.2%) were at intermediate risk. Median preprocedural musclin levels were 2.7 ng/mL (quartile 1–quartile 3, 1.5–4.6 ng/mL). Musclin levels were dichotomized in low (<2.862 ng/mL, n=199 [54.1%]) or high (≥ 2.862 ng/mL, n=169 [45.9%]) groups using cutoff values determined by classification and regression tree analysis. The primary end point was 1‐year overall survival. Patients with low circulating musclin levels exhibited a significantly higher prevalence of frailty, low albumin values, hypertension, and history of stroke as well as higher N‐terminal pro‐B‐type natriuretic peptide. Low musclin levels significantly predicted risk of death in univariable (hazard ratio, 1.81; 95% CI, 1.00–3.53 [P=0.049]) and multivariable (adjusted hazard ratio, 2.45; 95% CI, 1.06–5.69 [P=0.037]) Cox regression analyses. Additionally, low musclin levels in combination with conventional EuroSCORE II suggested improved risk stratification in patients undergoing TAVI who were at low to intermediate clinical risk into subgroups with reduced 1‐year survival rates by log‐rank test (P for trend=0.003). CONCLUSIONS: Circulating musclin is an independent predictor of 1‐year overall survival in patients undergoing TAVI. Combined with EuroSCORE II, circulating musclin might help to improve prediction of mortality in patients undergoing TAVI who are at low to intermediate clinical risk. John Wiley and Sons Inc. 2022-03-01 /pmc/articles/PMC9075297/ /pubmed/35229655 http://dx.doi.org/10.1161/JAHA.121.022792 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Kattih, Badder
Carstens, Daniel C.
Boeckling, Felicitas
Rasper, Tina
Pergola, Graziella
Dimmeler, Stefanie
Vasa‐Nicotera, Mariuca
Zeiher, Andreas M.
Mas‐Peiro, Silvia
Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk
title Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk
title_full Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk
title_fullStr Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk
title_full_unstemmed Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk
title_short Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low‐Intermediate Risk
title_sort low circulating musclin is associated with adverse prognosis in patients undergoing transcatheter aortic valve implantation at low‐intermediate risk
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075297/
https://www.ncbi.nlm.nih.gov/pubmed/35229655
http://dx.doi.org/10.1161/JAHA.121.022792
work_keys_str_mv AT kattihbadder lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT carstensdanielc lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT boecklingfelicitas lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT raspertina lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT pergolagraziella lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT dimmelerstefanie lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT vasanicoteramariuca lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT zeiherandreasm lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk
AT maspeirosilvia lowcirculatingmusclinisassociatedwithadverseprognosisinpatientsundergoingtranscatheteraorticvalveimplantationatlowintermediaterisk